Compare AbbVie Inc (ABBV) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? AbbVie Inc trades at $253.73 (market cap $449.91B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.65. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | VTIP | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $50.75 |
52-Week Low | $184.85 | $49.39 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
VTIP (Vanguard Short-Term Inflation-Protected Securities ETF) trades at $49.64 with minimal daily movement (+0.12%). The technical picture shows conflicting signals with moving averages indicating bearish pressure while oscillators suggest potential oversold conditions. Recent news highlights VTIP's role as an inflation hedge, with multiple institutional investors increasing positions. The ETF focuses on short-term Treasury Inflation-Protected Securities, designed to protect against rising consumer prices.
VTIP offers investors exposure to inflation-protected government bonds with lower duration risk than longer-term TIPS funds. Current market conditions favor inflation-hedging assets, though the fund faces risks from potential Fed policy shifts and interest rate volatility. The ETF's structure provides built-in CPI adjustment, making it relevant in the current inflationary environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
